Adverum Biotech doses first subject in phase 2 trial to treat wet AMD

• Adverum Biotechnologies (ADVM) said on Wednesday the first subject had been dosed in the Phase 2 trial testing ixoberogene soroparvovec to treat wet age-related macular degeneration.
• The trial is designed to assess the safety and efficacy of two dose levels of a single, in-office intravitreal injection of Ixo-vec for the treatment of wet AMD.
• The trial, dubbed LUNA, primary endpoints are mean change in BCVA from baseline to one year and the incidence and severity of adverse events.